In vitro effects of VA441, a new selective cyclooxygenase-2 inhibitor, on human osteoarthritic chondrocytes exposed to IL-1β

Journal of Pharmacological Sciences

Volumn 120, Issue 1, 2012, Pages 6-14

  Fioravanti, Antonella ^a   Tinti, Laura ^a   Pascarelli, Nicola Antonio ^a   Di Capua, Angela ^a   Lamboglia, Antonello ^a   Cappelli, Andrea ^a   Biava, Mariangela ^b   Giordani, Antonio ^c   Niccolini, Silvia ^a   Galeazzi, Mauro ^a   Anzini, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Rotta Research Laboratorium   (Italy)

Author keywords

Celecoxib; Chondrocyte; Cyclooxygenase 2 inhibitor; Indomethacin; VA441

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NITRIC OXIDE; PROSTAGLANDIN E2; STROMELYSIN; UNCLASSIFIED DRUG; VA 441; [2 METHYL 5 (4 METHYLSULPHONYL)PHENYL 1 PHENYL 3 (2 N PROPYLOXYETHYL)] 1H PYRROLE;

ARTICLE; CARTILAGE CELL; CELL METABOLISM; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MORPHOLOGY; OSTEOARTHRITIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

EID: 84866561670     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12016FP     Document Type: Article

References (52)

1. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;26:355-369.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol. 1971;231:232-235.
3. Ofman JJ, Maclean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A meta-analysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs. J Rheumatol. 2002;29:804-812.
4. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum. 2002;32 Suppl 1:33-42.
5. DeWitt DL. Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol. 1999;55:625-631.
6. Grosser T, Fries S, Fitzgerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4-15.
7. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006;98: 266-274.
8. Fries S, Grosser T, Price TS, Lawson JA, Kapoor S, De Marco S, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology. 2006; 130:55-64.
9. Brandt KD. Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism, in vitro and in vivo. Am J Med. 1987; 83 Suppl 5A:29-34.
10. Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation. 2002;26:139-142.
11. Smith RL, Kajiyama G, Lane NE. Nonsteroidal antiinflammatory drugs: effects on normal and interleukin 1 treated human articular chondrocyte metabolism in vitro. J Rheumatol. 1995;22:1130-1137.
12. Henrotin Y, Reginster JY. In-vitro differences among nonsteroidal antiinflammatory drugs in their activities related to osteoarthritis pathophysiology. Osteoarthritis Cartilage. 1999;7:355-357.
13. Sadowski T, Steinmeyer J. Effects of non-steroidal antiinflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by bovine articular chondrocytes. Osteoarthritis Cartilage. 2001;9:407-415.
14. Mastbergen SC, Lafeber FP, Bijlsma JW. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford). 2002;41:801-808.
15. Iimoto S, Watanabe S, Takahashi T, Shimizu A, Yamamoto H. The influence of Celecoxib on matrix synthesis by chondrocytes under mechanical stress in vitro. Int J Mol Med. 2005;16: 1083-1088.
16. Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther. 2006;8:R2.
17. Nakamura H, Masuko K, Yudoh K, Kato T, Nishioka K. Effects of celecoxib on human chondrocytes-enhanced production of chemokines. Clin Exp Rheumatol. 2007;25:11-16.
18. Biava M, Porretta GC, Cappelli A, Vomero S, Manetti F, Botta M, et al. 1,5-Diarylpyrrole-3-acetic and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors. J Med Chem. 2005;48:3428-3432.
19. Di Bari L, Pescitelli G, Salvadori P, Rovini M, Anzini M, Cappelli A, et al. Synthesis, resolution, and absolute configuration of two novel and selective cyclooxygenase-2 inhibitors based on the 1,5-diarylpyrrole structure. Tetrahedron Asymmetry. 2006;17:3430-3436.
20. Biava M, Porretta GC, Poce G, Supino S, Forli S, Rovini M, et al. Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrole-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxigenase-2/ cyclooxygenase-1 selectivity. J Med Chem. 2007;50:5403-5411.
21. Anzini M, Rovini M, Cappelli A, Vomero S, Biava M, Ghelardini C, et al. Synthesis, biological evaluation, and enzyme docking simulations of 1,5 diarylpyrrole-3-alkoxethyl esters as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. J Med Chem. 2008;51:4476-4481.
22. Daheshia M, Yao JQ. The Interleukin 1β pathway in the pathogenesis of osteoarthritis. J Rheumatol. 2008;35:2306-2312.
23. Altman R, Alarcon G, Appelrouth D, Bloch D, Borestein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505-514.
24. Mastbergen SC, Bijlsma JW, Lafeber FP. Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage. 2005;13:519-526.
25. Gross SS, Jaffee EA, Levi R, Kilbourn RE. Cytokine-activated endothelial cells express an isotope of nitric oxide synthase which is tetrahydrobiopterin- dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem Biophys Res Commun. 1991;178:823-829.
26. Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett. 2003;339:62-66.
27. Pfaffl MW. A new mathemathical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
28. Lazzerini PE, Capecchi Pl, Nerucci F, Fioravanti A, Chellini F, Piccini M, et al. Simvastatin reduces MMP-3 level in interleukin 1β stimulated human chondrocyte culture. Ann Rheum Dis. 2004;63:867-869.
29. Karnovsky MG. A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy. J Cell Biol. 1965;27:137A.
30. Fioravanti A, Moretti E, Scapigliati G, Cervone R, Galeazzi M, Collodel G. Morphological, immunocytochemical and biochemical studies in human osteoarthritic chondrocytes exposed to IL- 1β and cyclical hydrostatic pressure. Clin Exp Rheumatol. 2007;25:690-695.
31. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res. 2004;427 Suppl:S27-S36.
32. Héraud F, Héraud A, Harmand MF. Apoptosis in normal and osteoarthritic human articular cartilage. Ann Rheum Dis. 2000;59:959-965.
33. Lopez-Armada MJ, Carames B, Lires-Dean M, Cillero-Pastor B, Ruiz-Romero C, Galdo F, et al. Cytokines, tumor necrosis factor-alpha and interleukin-1beta, differentially regulate apoptosis in osteoarthritis cultured human chondrocytes. Osteoarthritis Cartilage. 2006;14:660-669.
34. Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum. 2002;46:1789-1803.
35. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum. 2003;33:155-167.
36. Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ, Rediske J, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest. 1997;99:1231-1237.
37. Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res. 2004;427:S37-S46.
38. Dingle JT. Prostaglandins in human cartilage metabolism. J Lipid Mediat. 1993;6:303-312.
39. Di Battista JA, Martel-Pelletier J, Fujimoto N, Obata K, Zafarullah M, Pelletier JP. Prostaglandins E2 and E1 inhibit cytokine induced metalloprotease expression in human synovial fibroblasts: mediation by cyclic-AMP signalling pathway. Lab Invest. 1994;71:270-278.
40. El Hajjaji H, Marcelis A, Devogelaer JP, Manicourt DH. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol. 2003;30:2444-2451.
41. Li X, Ellman M, Muddasani P, Wang JH, Cs-Szabo G, van Wijnen AJ, et al. Prostaglandin E2 and its cognate EP receptors control human adult articular cartilage homeostasis and are linked to the pathophysiology of osteoarthritis. Arthritis Rheum. 2009;60:513-523.
42. Di Battista JA, Doré S, Martel-Pelletier J, Pelletier JP. Prostaglandin E2 stimulates incorporation of proline into collagenase digestible proteins in human articular chondrocytes: identification of an effector autocrine loop involving insulin-like growth factor I. Mol Cell Endocrinol. 1996;123:27-35.
43. Mitrovic D, McCall E, Dray F. The in vitro production of prostanoids by cultured bovine articular chondrocytes. Prostaglandins. 1982;23:17-28.
44. Abramson SB. Osteoarthritis and nitric oxide. Osteoarthtritis Cartilage. 2008;16 Suppl 2:S15-S20.
45. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum. 1998;41:1275-1286.
46. Matsuda K, Nakamura S, Matsushita T. Celocoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints. Rheumatol Int. 2006;26:991-995.
47. Mastbergen SC, Bijlsma JW, Lafeber FP. Synthesis and release of human cartilage matrix proteoglycans are differently regulated by nitric oxide and prostaglandin-E2. Ann Rheum Dis. 2007;67:52-58.
48. Tsutsumi R, Ito H, Hiramitsu T, Nishitani K, Akiyoshi M, Kitoari T, et al. Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes. Rheumatol Int. 2008;28:727-736.
49. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057-2072.
50. Cawston TE, Young DA. Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell Tissue Res. 2010;339:221-235.
51. De Boer TN, Huisman AM, Polak AA, Niehoff AG, van Rinsum AC, Saris D, et al. The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment. Osteoarthritis Cartilage. 2009;17:482-488.
52. Zweers MC, de Boer TN, van Roon J, Bijlsma JW, Lafeber FP, Mastbergen SC. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther. 2011;13:239.